Medpace (NASDAQ:MEDP) Posts Earnings Results, Beats Estimates By $0.75 EPS

Medpace (NASDAQ:MEDP) issued its quarterly earnings results on Monday. The company reported $3.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75, Briefing.com reports. The business had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a return on equity of 65.98% and a net margin of 15.92%. The business’s quarterly revenue was up 17.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.27 earnings per share. Medpace updated its FY24 guidance to $10.79-11.47 EPS and its FY 2024 guidance to 10.790-11.470 EPS.

Medpace Stock Performance

NASDAQ:MEDP opened at $407.15 on Wednesday. Medpace has a one year low of $187.03 and a one year high of $419.42. The firm has a market cap of $12.61 billion, a price-to-earnings ratio of 41.50, a PEG ratio of 1.99 and a beta of 1.38. The firm’s fifty day moving average is $397.68 and its two-hundred day moving average is $323.14.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the transaction, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the transaction, the insider now owns 5,525,959 shares of the company’s stock, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,340 shares of company stock valued at $76,651,647. 20.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and upped their price target for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and boosted their price objective for the company from $340.00 to $450.00 in a report on Tuesday. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective on the stock. Robert W. Baird boosted their price objective on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a report on Wednesday, February 14th. Finally, StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $395.60.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.